Patents by Inventor Tan Ince
Tan Ince has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240226074Abstract: Accurate methods for detecting cancer and for determining the prognosis of cancer, including breast cancer, are described herein, using biomarkers referred to herein as the ET-29, HDAC1, HDAC7, and ZNF92. Upregulation of HDAC1, HDAC7, and ZNF92 and optionally one or more genes in ET-29 biomarkers predicts sensitivity to a three-drug combination that includes histone deacetylase inhibitor(s) (HDAC), heat shock protein 90 (HSP90) inhibitor(s), and helminth(s).Type: ApplicationFiled: December 14, 2023Publication date: July 11, 2024Inventor: Tan A. Ince
-
Patent number: 11530385Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: August 1, 2017Date of Patent: December 20, 2022Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.Inventors: Tan A. Ince, Robert A. Weinberg
-
Patent number: 11332712Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.Type: GrantFiled: October 10, 2019Date of Patent: May 17, 2022Assignee: UNIVERSITY OF MIAMIInventor: Tan Ince
-
Publication number: 20220016135Abstract: The invention provides a classification and treatment system for breast cancer using measurements of and ligands for estrogen receptor, androgen receptor, vitamin D receptor, and optionally HER2 receptor.Type: ApplicationFiled: July 16, 2020Publication date: January 20, 2022Inventor: Tan Ince
-
Publication number: 20200040301Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.Type: ApplicationFiled: October 10, 2019Publication date: February 6, 2020Inventor: Tan Ince
-
Patent number: 10465166Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.Type: GrantFiled: August 25, 2017Date of Patent: November 5, 2019Assignee: UNIVERSITY OF MIAMIInventor: Tan Ince
-
Publication number: 20190071634Abstract: Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.Type: ApplicationFiled: August 7, 2018Publication date: March 7, 2019Inventor: Tan A. INCE
-
Publication number: 20180282691Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: ApplicationFiled: August 1, 2017Publication date: October 4, 2018Inventors: Tan A. Ince, Robert A. Weinberg
-
Publication number: 20180155687Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: ApplicationFiled: July 10, 2017Publication date: June 7, 2018Inventors: Tan A. Ince, Robert A. Weinberg
-
Publication number: 20170349878Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.Type: ApplicationFiled: August 25, 2017Publication date: December 7, 2017Applicant: UNIVERSITY OF MIAMIInventor: Tan Ince
-
Patent number: 9777256Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.Type: GrantFiled: September 24, 2014Date of Patent: October 3, 2017Assignee: UNIVERSITY OF MIAMIInventor: Tan A. Ince
-
Patent number: 9696313Abstract: In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer.Type: GrantFiled: October 5, 2012Date of Patent: July 4, 2017Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.Inventors: Sandro Santagata, Susan Lindquist, Luke J. Whitesell, Tan A. Ince
-
Patent number: 9683217Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.Type: GrantFiled: April 12, 2013Date of Patent: June 20, 2017Assignees: UNIVERSITY OF MIAMI, The Brigham and Women's Hospital, Inc.Inventors: Tan A. Ince, Jon C. Aster
-
Publication number: 20170058259Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.Type: ApplicationFiled: September 24, 2014Publication date: March 2, 2017Inventor: Tan A. Ince
-
Publication number: 20160319239Abstract: Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.Type: ApplicationFiled: May 5, 2016Publication date: November 3, 2016Inventor: Tan A. Ince
-
Publication number: 20160146819Abstract: A novel classification system for breast cancer based on normal breast cell phenotypes and various expression levels of estrogen receptor (ER), androgen receptor (AR), and vitamin D receptor (VDR). The various categories of the classification system are associated with different survival rates and prognoses. The invention includes a method of classifying breast cancer comprises measuring the levels of ER, AR, and VDR in the cancerous tissue, and classifying the breast cancer into one of the above-noted categories according to expression levels. The invention includes a method of predicting the prognosis of breast cancer in a patient and a method of determining a treatment regimen for breast cancer depending on the category in which the breast cancer is classified. The invention includes a method of treating breast cancer according to the expression profile of ER, AR, and VDR detected in the cancerous tissue. Kits for detecting the same are also provided.Type: ApplicationFiled: June 19, 2014Publication date: May 26, 2016Applicant: University of MiamiInventor: Tan A. Ince
-
Publication number: 20160102365Abstract: Described herein are assays, methods and kits for analyzing sensitivity of a subject's cancerous tumor to a drug, predicting responses of cancerous tumors to drugs, determining the prognosis of a subject having a cancerous tumor, and developing a personalized therapy or treatment strategy for the subject. The assays, methods and kits involve analyzing gene and protein expression signatures or profiles of a subject's cancerous tumor, testing candidate drugs in cancerous cells from the subject's cancerous tumor, and classifying a subject's cancerous tumor based on ovarian cell and fallopian tube cell cell-of-origin gene expression signatures. Using these methods, a suitable drug (or drugs) is identified, the subject can be treated with that drug, and a personalized therapy can be developed for the subject.Type: ApplicationFiled: June 4, 2014Publication date: April 14, 2016Inventor: Tan A. Ince
-
Publication number: 20150259644Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: ApplicationFiled: December 15, 2014Publication date: September 17, 2015Inventors: Tan A. Ince, Robert A. Weinberg
-
Publication number: 20150119557Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.Type: ApplicationFiled: April 12, 2013Publication date: April 30, 2015Applicants: THE UNIVERSITY OF MIAMI, THE BRITISH COLUMBIA CANCER AGENCY BRANCH, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Andrew P. Weng, Jon C. Aster, Tan A. Ince
-
Patent number: 8936939Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: July 23, 2012Date of Patent: January 20, 2015Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.Inventors: Tan A. Ince, Robert A. Weinberg